FREQ - Frequency Therapeutics, Inc.
After hours:
| Previous Close | 0.3589 |
| Open | 0.3603 |
| Bid | 0.3520 x 1200 |
| Ask | 0.3548 x 4000 |
| Day's Range | 0.3501 - 0.3660 |
| 52 Week Range | 0.3500 - 5.5900 |
| Volume | |
| Avg. Volume | 271,843 |
| Market Cap | 12.595M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1700 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Business Wire
Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
LEXINGTON, Mass., May 12, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2023.
- Business Wire
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
LEXINGTON, Mass., March 10, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.
- Business Wire
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
LEXINGTON, Mass., February 27, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences:
- Business Wire
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
LEXINGTON, Mass., February 13, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL).
Business WireFrequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
LEXINGTON, Mass., December 19, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has established a Clinical Advisory Board to help guide its remyelination in multiple sclerosis (MS) program. Comprised of leading experts from across the neurosciences, the Clinical Advisory Board will support clinical development and translation eff
- Business Wire
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
LEXINGTON, Mass., December 15, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Company’s second hearing restoration candidate for sensorineural hearing loss (SNHL).
- Business Wire
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
LEXINGTON, Mass., November 17, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it will host a virtual investor event on December 13, 2022, with a focus on FX-322, the Company’s lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical r
- Business Wire
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
LEXINGTON, Mass., November 08, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.
- Business Wire
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
LEXINGTON, Mass., October 12, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show improvement in a pre-specified measure of s
- Business Wire
Frequency Therapeutics to Participate in September Investor and Medical Conferences
LEXINGTON, Mass., August 30, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that members of its management team will participate in investor and medical conferences later this month.
- Business Wire
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
LEXINGTON, Mass., August 09, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the second quarter ended June 30, 2022.
Simply Wall St.Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week
Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders will doubtless be very grateful to see the share price up 41...